Literature DB >> 19664379

ApoB versus non-HDL-C: what to do when they disagree.

Allan Sniderman1, Ken Williams, Christa Cobbaert.   

Abstract

The high correlation between apolipoprotein B (apoB) and non-high-density lipoprotein cholesterol (non-HDL-C) is the chief argument employed against introducing apoB into clinical practice. However, high correlation does mean that non-HDL-C and apoB will often yield similar clinical information. Nevertheless, the critical issue is not how often the two tests agree, but how often, and how substantially, they differ. In other words, how often would an apoB result change a clinical decision based on a value for non-HDL-C? This article presents a series of examples from prominent published studies in which apoB and non-HDL-C differ so dramatically that diagnosis and therapy would truly differ depending on which index was used by the physician. These examples establish that apoB and non-HDL-C are not clinical equivalents.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19664379     DOI: 10.1007/s11883-009-0054-2

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN: 1523-3804            Impact factor:   5.113


  15 in total

1.  When should a new test become the current reference standard?

Authors:  Paul Glasziou; Les Irwig; Jonathan J Deeks
Journal:  Ann Intern Med       Date:  2008-12-02       Impact factor: 25.391

2.  Differential response of cholesterol and particle measures of atherogenic lipoproteins to LDL-lowering therapy: implications for clinical practice.

Authors:  Allan D Sniderman
Journal:  J Clin Lipidol       Date:  2008-01-08       Impact factor: 4.766

3.  Diagnosis of type III hyperlipoproteinemia from plasma total cholesterol, triglyceride, and apolipoprotein B.

Authors:  Allan Sniderman; Andre Tremblay; Jean Bergeron; Claude Gagné; Patrick Couture
Journal:  J Clin Lipidol       Date:  2007-07-27       Impact factor: 4.766

4.  Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia.

Authors:  J L Goldstein; H G Schrott; W R Hazzard; E L Bierman; A G Motulsky
Journal:  J Clin Invest       Date:  1973-07       Impact factor: 14.808

5.  International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. IV. Comparability of apolipoprotein B values by use of International Reference Material.

Authors:  S M Marcovina; J J Albers; H Kennedy; J V Mei; L O Henderson; W H Hannon
Journal:  Clin Chem       Date:  1994-04       Impact factor: 8.327

6.  Nomogram to diagnose familial combined hyperlipidemia on the basis of results of a 5-year follow-up study.

Authors:  Mario J Veerkamp; Jacqueline de Graaf; Jan C M Hendriks; Pierre N M Demacker; Anton F H Stalenhoef
Journal:  Circulation       Date:  2004-06-07       Impact factor: 29.690

7.  Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment.

Authors:  John J P Kastelein; Wim A van der Steeg; Ingar Holme; Michael Gaffney; Nilo B Cater; Philip Barter; Prakash Deedwania; Anders G Olsson; S Matthijs Boekholdt; David A Demicco; Michael Szarek; John C LaRosa; Terje R Pedersen; Scott M Grundy
Journal:  Circulation       Date:  2008-06-02       Impact factor: 29.690

8.  High-density lipoprotein particle size and concentration and coronary risk.

Authors:  Karim El Harchaoui; Benoit J Arsenault; Remco Franssen; Jean-Pierre Després; G Kees Hovingh; Erik S G Stroes; James D Otvos; Nicholas J Wareham; John J P Kastelein; Kay-Tee Khaw; S Matthijs Boekholdt
Journal:  Ann Intern Med       Date:  2009-01-20       Impact factor: 25.391

9.  Non-HDL cholesterol and apoB in dyslipidaemia.

Authors:  Allan D Sniderman; Jean-Charles Hogue; Jean Bergeron; Claude Gagné; Patrick Couture
Journal:  Clin Sci (Lond)       Date:  2008-01       Impact factor: 6.124

10.  Familial hypoalphalipoproteinemia in premature coronary artery disease.

Authors:  J Genest; J M Bard; J C Fruchart; J M Ordovas; E J Schaefer
Journal:  Arterioscler Thromb       Date:  1993-12
View more
  12 in total

Review 1.  Lipid parameters for measuring risk of cardiovascular disease.

Authors:  Benoit J Arsenault; S Matthijs Boekholdt; John J P Kastelein
Journal:  Nat Rev Cardiol       Date:  2011-02-01       Impact factor: 32.419

2.  To B or not to B: is non-high-density lipoprotein cholesterol an adequate surrogate for apolipoprotein B?

Authors:  Carl J Lavie; Richard V Milani; James H O'Keefe
Journal:  Mayo Clin Proc       Date:  2010-05       Impact factor: 7.616

3.  Relation of cholesterol and lipoprotein parameters with carotid artery plaque characteristics: the Atherosclerosis Risk in Communities (ARIC) carotid MRI study.

Authors:  Salim S Virani; Diane J Catellier; Lisa A Pompeii; Vijay Nambi; Ron C Hoogeveen; Bruce A Wasserman; Josef Coresh; Thomas H Mosley; James D Otvos; A Richey Sharrett; Eric Boerwinkle; Christie M Ballantyne
Journal:  Atherosclerosis       Date:  2011-08-07       Impact factor: 5.162

Review 4.  The evolution and refinement of traditional risk factors for cardiovascular disease.

Authors:  Emil M deGoma; Joshua W Knowles; Fabio Angeli; Matthew J Budoff; Daniel J Rader
Journal:  Cardiol Rev       Date:  2012 May-Jun       Impact factor: 2.644

Review 5.  The role of triglycerides in atherosclerosis.

Authors:  Beatriz G Talayero; Frank M Sacks
Journal:  Curr Cardiol Rep       Date:  2011-12       Impact factor: 2.931

Review 6.  Opening a new lipid "apo-thecary": incorporating apolipoproteins as potential risk factors and treatment targets to reduce cardiovascular risk.

Authors:  Terry A Jacobson
Journal:  Mayo Clin Proc       Date:  2011-08       Impact factor: 7.616

7.  Association of apolipoprotein B, LDL-C and vascular stiffness in adolescents with type 1 diabetes.

Authors:  Petter Bjornstad; Nhung Nguyen; Christina Reinick; David M Maahs; Franziska K Bishop; Scott A Clements; Janet K Snell-Bergeon; Rachel Lieberman; Laura Pyle; Stephen R Daniels; R Paul Wadwa
Journal:  Acta Diabetol       Date:  2014-12-25       Impact factor: 4.280

Review 8.  Which Lipids Should Be Analyzed for Diagnostic Workup and Follow-up of Patients with Hyperlipidemias?

Authors:  Michel R Langlois; Børge G Nordestgaard
Journal:  Curr Cardiol Rep       Date:  2018-08-17       Impact factor: 2.931

9.  Reducing vascular events risk in patients with dyslipidaemia: an update for clinicians.

Authors:  Michel P Hermans; Jean-Charles Fruchart
Journal:  Ther Adv Chronic Dis       Date:  2011-09       Impact factor: 5.091

10.  Associations between intensive diabetes therapy and NMR-determined lipoprotein subclass profiles in type 1 diabetes.

Authors:  Ying Zhang; Alicia J Jenkins; Arpita Basu; Julie A Stoner; Maria F Lopes-Virella; Richard L Klein; Timothy J Lyons
Journal:  J Lipid Res       Date:  2015-12-09       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.